ARMATA PHARMACEUTICALS, INC. Increase Decrease In Operating Lease Liability
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Increase Decrease In Operating Lease Liability of -$652.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$331.00K.
- ARMATA PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$321.00K.
- ARMATA PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$265.00K.
- ARMATA PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$257.00K.
- ARMATA PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2025 was -$1.03M.
- ARMATA PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2024 was -$4.96M.
- ARMATA PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2023 was -$13.45M, a 469.23% decline from fiscal 2022.
- ARMATA PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2022 was $3.64M, a 630.06% increase from fiscal 2021.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 9 month as first filed | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$652.00K 10-Q · filed 2026-08-12 | -$917.00K derived: sum of 3 quarters · filed 2026-08-12 | -$1.17M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$321.00K 10-Q · filed 2026-05-13 | -$586.00K derived: sum of 2 quarters · filed 2026-05-13 | -$843.00K derived: sum of 3 quarters · filed 2026-05-13 | -$1.10M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$265.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$522.00K derived: sum of 2 quarters · filed 2026-03-25 | -$778.00K derived: sum of 3 quarters · filed 2026-08-12 | -$1.03M 10-K · filed 2026-03-25 | |
| 2025-09-30 | -$257.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$513.00K derived: sum of 2 quarters · filed 2026-08-12 | -$763.00K 10-Q · filed 2025-11-12 | -$1.56M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$506.00K 10-Q · filed 2026-08-12 | -$1.30M derived: sum of 3 quarters · filed 2026-08-12 | -$2.24M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$250.00K 10-Q · filed 2026-05-13 | -$1.05M derived: sum of 2 quarters · filed 2026-05-13 | -$1.99M derived: sum of 3 quarters · filed 2026-05-13 | -$3.03M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$798.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$1.74M derived: sum of 2 quarters · filed 2026-03-25 | -$2.78M derived: sum of 3 quarters · filed 2026-03-25 | -$4.96M 10-K · filed 2026-03-25 | |
| 2024-09-30 | -$938.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.98M derived: sum of 2 quarters · filed 2025-11-12 | -$4.16M 10-Q · filed 2025-11-12 | -$7.89M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$3.23M 10-Q · filed 2025-08-12 | -$6.95M derived: sum of 3 quarters · filed 2025-08-12 | -$9.20M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$2.18M 10-Q · filed 2025-05-14 | -$5.91M derived: sum of 2 quarters · filed 2025-05-14 | -$8.16M derived: sum of 3 quarters · filed 2025-05-14 | -$11.97M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$5.98M derived: sum of 2 quarters · filed 2025-03-21 | -$9.79M derived: sum of 3 quarters · filed 2025-03-21 | -$13.45M 10-K · filed 2025-03-21 | |
| 2023-09-30 | -$2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$6.06M derived: sum of 2 quarters · filed 2024-11-13 | -$9.72M 10-Q · filed 2024-11-13 | -$7.54M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$3.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$7.47M 10-Q · filed 2024-08-13 | -$5.29M derived: sum of 3 quarters · filed 2024-08-13 | -$5.61M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | -$3.66M 10-Q · filed 2024-05-07 | -$1.48M derived: sum of 2 quarters · filed 2024-05-07 | -$1.80M derived: sum of 3 quarters · filed 2024-05-07 | -$911.00K derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.86M derived: sum of 2 quarters · filed 2024-03-21 | $2.75M derived: sum of 3 quarters · filed 2024-03-21 | $3.64M 10-K · filed 2024-03-21 | |
| 2022-09-30 | -$324.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $567.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.46M 10-Q · filed 2023-11-14 | $2.67M 10-Q · filed 2022-11-09 | $1.81M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $891.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.78M 10-Q · filed 2023-08-14 | $2.13M derived: sum of 3 quarters · filed 2023-08-14 | $2.18M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $890.00K 10-Q · filed 2023-05-11 | $1.24M derived: sum of 2 quarters · filed 2023-05-11 | $1.29M derived: sum of 3 quarters · filed 2023-05-11 | $1.34M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $354.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $402.00K derived: sum of 2 quarters · filed 2023-03-16 | $450.00K derived: sum of 3 quarters · filed 2023-03-16 | $499.00K 10-K · filed 2023-03-16 | |
| 2021-09-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $96.00K derived: sum of 2 quarters · filed 2022-11-09 | $145.00K 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $97.00K 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $49.00K 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | $803.00K 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |